{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1380021393550031753.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Maria Lagerström Fermer"}],"foaf:familyName":[{"@value":"Fermer"}],"foaf:givenName":[{"@value":"Maria Lagerström"}]}],"career":[{"institution":{"notation":[{"@value":"Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.F., L.-M.G.)."}]}}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1360021393550031744","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1161/circulationaha.120.045810"},{"@type":"URI","@value":"https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.120.045810"}],"notation":[{"@value":"Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1161/circulationaha.120.045810_SwWL2fAiAFKxOv0FpiUzW3d9w49"}]}